WESTMINSTER, CA / ACCESSWIRE / December 20, 2023 / BioLargo, Inc. (OTCQB:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it received a purchase order for its Aqueous Electrostatic Concentrator (AEC) to be installed at a water treatment facility in Stockholm, New Jersey. BioLargo's AEC is an eco-friendly water treatment technology for effectively removing per- and polyfluoroalkyl substances (PFAS) from contaminated water, including drinking water.

Compared to technologies like carbon filtration or ion exchange, the BioLargo AEC produces far less PFAS-laden waste during the PFAS removal process, significantly reducing potential hazardous waste disposal costs associated with PFAS remediation projects, and is able to remove all specified PFAS chemicals from water below EPA and state requirements.

Once the AEC system is installed, BioLargo will enter into an ongoing service contract for the maintenance of the system as well as the removal and disposal and destruction of the PFAS-laden waste.

John W. Clark, Jr. President of Lake Stockholm Systems, Inc. said, "After an extensive review of the available technologies, including input from our engineers and the state of New Jersey, we selected the BioLargo AEC to ensure the drinking water in our community was free of harmful PFAS chemicals. BioLargo's solution will give us the peace of mind and guarantee that we can meet remediation requirements, both today and in the future."

BioLargo's President and CEO Dennis P. Calvert commented, "Lake Stockholm Systems recognized our technology as a more eco-friendly, regulation-friendly, and cost-effective long-term solution for treating water contaminated by PFAS. We believe the success of this project will play a big role in attracting further municipal water treatment customers, many of whom are still under the misconception that carbon filtration or ion exchange are the only options for long-term PFAS remediation."

Mr. Calvert continued, "Our technology reduces costs customers pay to dispose of the harmful and hazardous waste produced by any technology removing PFAS from water. For example, where a carbon system might produce 80,000 pounds of hazardous spent carbon at the end of its life, we can treat the same volume of water and produce less than five pounds of solid waste. With CERCLA and RCRA regulations looming, which will require handling PFAS-laden solid waste as hazardous materials, legacy technologies simply won't be able to compete with the AEC in this area."

Learn more at www.bestPFAStreatment.com.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

SOURCE: BioLargo, Inc.